Adam Davidson, CEO of Trident Royalties, discusses offtake milestones and catalysts to boost FY24. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOxford Biomedica Share News (OXB)

Share Price Information for Oxford Biomedica (OXB)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 314.00
Bid: 313.00
Ask: 315.00
Change: -14.00 (-4.27%)
Spread: 2.00 (0.639%)
Open: 335.00
High: 351.00
Low: 311.50
Prev. Close: 328.00
OXB Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

EU rebuffs UK calls to ship AstraZeneca COVID vaccines from Europe

Sun, 21st Mar 2021 20:57

By Francesco Guarascio

BRUSSELS, March 21 (Reuters) - The European Union is
rebuffing British government calls to ship AstraZeneca
COVID-19 vaccines produced in a factory in the Netherlands, an
EU official said on Sunday.

Former EU member Britain has so far administered many more
vaccines than EU countries in proportion to the population.

"The Brits are insisting that the Halix plant in the
Netherlands must deliver the drug substance produced there to
them. That doesn't work," the official told Reuters.

The Leiden-based plant which is run by sub-contractor Halix
is listed as a supplier of vaccines in both the contracts that
AstraZeneca has signed with Britain and with the European Union.

"What is produced in Halix has to go to the EU," the
official added.

Britain has insisted that contracts must be respected.

"The European Commission will know that the rest of the
world is looking at the Commission, about how it conducts itself
on this, and if contracts get broken, and undertakings, that is
a very damaging thing to happen for a trading bloc that prides
itself on the rules of law," Defence Minister Ben Wallace said
on Sky News earlier in answer to a question about Commission
President Ursula Von der Leyen's threat to block exports to
Britain.

The EU official said the EU was not breaking any contract.

The European Union threatened on Wednesday to block exports
of COVID-19 vaccines to Britain to safeguard scarce doses for
its own citizens, with Von der Leyen saying the epidemiological
situation was worsening.

AstraZeneca has not yet sought approval in the EU for Halix,
but the official and a second EU source said the request was on
its way.

Without regulatory approval, vaccines produced at Halix
cannot be used in the EU.

An internal AstraZeneca document seen by Reuters shows that
the company expects EU approval on March 25.

AstraZeneca has declined to comment on the amount of
vaccines that are currently stockpiled at Halix.

The EU official said the factory had already produced shots,
but was not able to quantify the output. Under the EU contract
with AstraZeneca, vaccines must be produced before approval and
be delivered immediately afterwards.

Two factories in Britain run by Oxford Biomedica and Cobra
Biologics are also listed as suppliers to the EU in the contract
with AstraZeneca, but no vaccine has so far been shipped from
Britain to the EU, despite Brussels' earlier requests.

Officials have said that Cobra is not fully operational.
AstraZeneca told EU officials that the UK is using a clause in
its supply contract that prevents export of its vaccines until
the British market is fully served, EU officials said.
(Reporting by Francesco Guarascio @fraguarascio; Editing by
Giles Elgood)

More News
28 Jan 2022 09:56

Oxford Biomedica creates venture with Homology, launches £80m fundraise

(Sharecast News) - Cell and gene therapy specialist Oxford Biomedica announced an agreement with Homology Medicines on Friday, as well as a placing to raise £80m from new and existing shareholders, including a retail offer through the PrimaryBid platform.

Read more
17 Jan 2022 09:32

Oxford Biomedica starts search for new CEO as Dawson steps down

Oxford Biomedica starts search for new CEO as Dawson steps down

Read more
17 Jan 2022 07:10

Oxford Biomedica CEO John Dawson to step down

(Sharecast News) - Oxford Biomedica chief executive John Dawson said he was stepping down after 13 years at the helm of the Gene and cell therapy firm which helped develop a Covid-19 vaccine with AstraZeneca.

Read more
5 Jan 2022 08:54

Oxford Biomedica wins new agreement for LentiVector platform

Oxford Biomedica wins new agreement for LentiVector platform

Read more
5 Jan 2022 07:29

Oxford Biomedica signs licence, supply deal with Cabaletta Bio

(Sharecast News) - Gene and cell therapy group Oxford Biomedica on Wednesday said it had signed a new license and supply agreement on its LentiVector platform with US-based Cabaletta Bio.

Read more
15 Dec 2021 09:33

LONDON BROKER RATINGS: BofA starts Pod Point at Buy; Barclays cuts DCC

LONDON BROKER RATINGS: BofA starts Pod Point at Buy; Barclays cuts DCC

Read more
13 Dec 2021 10:03

Oxford Biomedica in license and supply deals with Novartis and Arcellx

Oxford Biomedica in license and supply deals with Novartis and Arcellx

Read more
13 Dec 2021 07:31

Oxford Biomedica strikes new license and supply agreements

(Sharecast News) - Gene and cell therapy group Oxford Biomedica has struck new license and supply agreements for its lentiviral vectors.

Read more
19 Oct 2021 10:50

Oxford BioMedica licences technology for cystic fibrosis treatment

Oxford BioMedica licences technology for cystic fibrosis treatment

Read more
19 Oct 2021 09:18

Boehringer Ingelheim licenses Oxford Biomedica's lentiviral vector technology

(Sharecast News) - Gene and cell therapy firm Oxford Biomedica said on Tuesday that pharmaceutical giant Boehringer Ingelheim had exercised its option to license its lentiviral vector technology to manufacture, register and commercialise a treatment for cystic fibrosis.

Read more
30 Sep 2021 09:35

LONDON BROKER RATINGS: Keppler Cheuvreux raises Pearson to Hold

LONDON BROKER RATINGS: Keppler Cheuvreux raises Pearson to Hold

Read more
28 Sep 2021 09:40

LONDON BROKER RATINGS: Investec prefers 888 over Entain

LONDON BROKER RATINGS: Investec prefers 888 over Entain

Read more
22 Sep 2021 16:54

LONDON MARKET CLOSE: Stocks up as Evergrande fears soothed before Fed

LONDON MARKET CLOSE: Stocks up as Evergrande fears soothed before Fed

Read more
22 Sep 2021 09:16

TOP NEWS: Oxford BioMedica sales double; Serum Institute buys stake

TOP NEWS: Oxford BioMedica sales double; Serum Institute buys stake

Read more
22 Sep 2021 07:03

Oxford Biomedica swings to profit on Covid-19 vaccine sales

(Sharecast News) - Covid-19 vaccine producer Oxford Biomedica swung to a profit in the half year on the back of a surge in revenues through its partnership deal with AstraZeneca and announced that Serum Institute of India has agreed to invest £50m in the group in return for a 3.9% stake in the company.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.